The global hypertrophic cardiomyopathy (HCM) therapeutics market is estimated to grow at a CAGR of nearly 1.5% during the forecast period. The significant prevalence of CVD is the major factor contributing to the market growth. As per the World Health Organization (WHO), CVDs are the major cause of mortality across the globe. In 2016, CVD accounted for nearly 17.9 million mortalities, which represented 31% of all global mortalities. 85% of these mortalities were reported due to stroke and heart attack. HCM is a genetic cardiac disease, which occurs due to the increase in wall thickness of left ventricle. It is usually caused by abnormal genes in the heart muscle, which cause left ventricle walls to become thicker and harder than normal.

Each child of a person with HCM has a 50% chance of inheriting the condition. In UK, nearly 1 in 500 people have the condition, however, most people who are suffering from this condition have few symptoms. The objective of HCM treatment is to provide relief from symptoms and avoid sudden cardiac death in people who are at high risk. Medications can support to slow the heart rate that facilitates the heart to pump blood better. The medications that are used for the treatment of HCM and its symptoms may comprise calcium channel blockers, beta-blockers, antiarrhythmic drugs, and anticoagulants. However, these medications have certain side-effects that may comprise low blood pressure and fluid in the lungs and in some cases, certain medications may cause sudden death. The increasing demand for surgeries such as septal myectomy, septal ablation, heart transplant, and implantable cardioverter defibrillator, to treat HCM is further expected to hinder the market growth.

Market Segmentation

The global HCM market is classified into drug class, which is further segmented into beta-adrenergic blocking agents, anticoagulants, antiarrhythmic agents, calcium channel blockers, and others. 

Antiarrhythmic Agents Finds Increasing Application in HCM Therapeutics

Antiarrhythmic agents enable to block irregular electrical activity, which in turn, supports the heart to beat normally. These medications can also support to prevent abnormal heart rhythms that occur due to the thickness of the heart’s walls. Sotolol (BetaPace) is considered as a useful drug for people suffering from arrhythmias. This drug may reduce blood pressure and seems to have some side effects. Additionally, Amiodarone (Cordarone) is the most commonly anti-arrhythmic drugs for HCM treatment that appears as a potent drug. However, it has several potentially severe side effects, such as hyperthyroidism, pulmonary toxicity, liver function abnormalities, proarrhythmia, and optic neuropathy, which can lead to blindness.

Disopyramide is another anti-arrhythmic drug that may be used for HCM therapeutics owing to its ability of obstruction relief in HCM. Owing to its antiarrhythmic effects, this drug may improve symptoms independently, possibly by decreasing the heart contraction force. Disopyramide (Norpace) has been used in Canada and Europe for a longer period in HCM therapeutics. Its adoption in the US is also increasing in HCM treatment. Disopyramide may be used in combination with beta?blockers to improve symptoms and lower intraventricular gradients among patients with Left ventricular outflow tract obstruction (LVOTO) by its negative inotropic effect. However, beta?blockers are considered as the most effective on provokable LVOTO and disopyramide is the most effective agent to reduce obstruction in the heart.

Global HCM Therapeutics Market Share by Drug Class, 2019 (%)

Regional Outlook

Geographically, in 2019, North America held the largest share in the market owing to the rising prevalence of cardiac diseases and significant awareness regarding CVD in the region. As per the Centers for Disease Control and Prevention (CDC), in the US, as many as 1 of 500 adults may have cardiomyopathy. Hypertrophic cardiomyopathy is believed to be the most common genetic cardiac disease, which occurs at any age, including young adults and children. This, in turn, is driving the demand for medications for HCM treatment to control symptoms and prevent sudden death. 

Global HCM Therapeutics Market Growth, by Region 2020-2026

Market Players Outlook 

The major players operating in the market include AstraZeneca plc, ANI Pharmaceuticals, Inc., MyoKardia, Inc., Bayer AG, and Sanofi S.A. MyoKardia, Inc., a clinical-stage biopharmaceutical company engaged in the development of precision medicine to treat CVD declared that it has regained global rights to all programs covered under its license and partnership agreement with Sanofi. In January 2019, MyoKardia and Sanofi end drug collaboration for heart disease. It is an end to a four-year partnership between the companies. This agreement was intended for combined development of small-molecule therapeutics, targeting genetic mutations that are associated with certain heart diseases. With this end of the agreement, MyoKardia has global rights to all programs in its portfolio, such as lead clinical-stage candidates, MYK-491 in dilated cardiomyopathy and mavacamten in obstructive HCM patients. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global HCM market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.